

Special Issue

Epigenetics in Cancer and Drug Therapeutics

Message from the Guest Editors

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- The role of chromatin remodeling complexes and histone modifiers in tumorigenesis and therapy resistance.
- Spatial genome architecture: insights from Hi-C and other 3D genome mapping techniques in understanding cancer aggressiveness and progression.
- The development and validation of DNA methylation, histone modification, or chromatin accessibility markers for diagnosis and treatment response.
- The development of small-molecule inhibitors or biologics targeting epigenetic regulators (e.g., DNMT, HDAC, proteins).
- Insights from single-cell and spatial epigenomics in dissecting intra-tumoral diversity and microenvironmental influences.
- Uncovering epigenetic mechanisms that drive metastasis, recurrence, and poor prognosis and associated therapeutic drug-based approaches.
- The synergistic use of epigenetic drugs with immune checkpoint inhibitors or other immunotherapeutics.

We look forward to receiving your contributions.

Guest Editors

Dr. Bethsebie Sailo

Department of Surgery, Center for Precision Medicine, University of Wisconsin Madison, Wisconsin, WI 53705, USA

Dr. Anup R. Sharma

Department of Surgery, Yale School of Medicine, New Haven, CT 06520, USA

Deadline for manuscript submissions

closed (10 May 2026)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/225622

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)